Navigation Links
'Self-seeding' of cancer cells may play a critical role in tumor progression
Date:12/24/2009

Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan-Kettering Cancer Center shows that circulating tumor cells cancer cells that break away from a primary tumor and disseminate to other areas of the body can also return to and grow in their tumor of origin, a newly discovered process called "self-seeding."

The findings of the study, published in the December 25 issue of the journal Cell, suggest that self-seeding can enhance tumor growth through the release of signals that promote angiogenesis, invasion, and metastasis.

"Our work not only provides evidence for the self-seeding phenomenon and reveals the mechanism of this process, but it also shows the possible role of self-seeding in tumor progression," said the study's first author Mi-Young Kim, PhD, Research Fellow in the Cancer Biology and Genetics Program at Memorial Sloan-Kettering.

According to the research, which was conducted in mice, self-seeding involves two distinct functions: the ability of a tumor to attract its own circulating progeny and the ability of circulating tumor cells to re-infiltrate the tumor in response to this attraction. The investigators identified four genes that are responsible for executing these functions: IL-6 and IL-8, which attract the most aggressive segment of the circulating tumor cells population, and FSCN1 and MMP1, which mediate the infiltration of circulating tumor cells into a tumor.

The findings also show that circulating breast cancer cells that are capable of self-seeding a breast tumor have a similar gene expression pattern to breast cancer cells that are capable of spreading to the lungs, bones, and brain, and therefore have an increased potential to metastasize to these organs. Additional experiments revealed that self-seeding can occur in cancer cells of various tumor types in addition to breast cancer, including colon cancer and melanoma.

"These results provide us with opportunities to explore new targeted therapies that may interfere with the self-seeding process and perhaps slow or even prevent tumor progression," said the study's senior author, Joan Massagu, PhD, Chair of the Cancer Biology and Genetics Program at Memorial Sloan-Kettering and a Howard Hughes Medical Institute investigator.

The concept of self-seeding sheds light on clinical observations such as the relationship between the tumor size, prognosis, and local relapse following seemingly complete removal of a primary breast tumor. "We know there is an association between large tumor size and poor prognosis. This was always thought to reflect the ability of larger cancers to release more cells with metastatic potential. But this association may actually be caused by the ability of aggressive cancer cells to self-seed, promoting both local tumor growth and distant metastases by similar mechanisms," said study co-author Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs at Memorial Sloan-Kettering.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
646-227-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Research Reveals How Breast Cancer Rearranges Genome
2. Alzheimers May Stave Off Cancer, and Vice Versa
3. Broken genomes behind breast cancers
4. Two Genes Work in Tandem to Spur Deadliest Brain Cancer
5. Rigel Receives Milestone Payment from Daiichi Sankyo for Cancer Ligase Target
6. New insights into mushroom-derived drug promising for cancer treatment
7. Ingredient in Botanicals Tied to Urinary Cancer
8. New iPhone App Provides New Services for Cancer Patients
9. Chicago Cancer Genome Project studies genetics of 1,000 tumors
10. UAB will carry out an in-depth study of the effects olive oil has on the prevention of breast cancer
11. Lung Cancer Foundation of America Gives the Gift of Life This Holiday Season: Announces Inaugural $125,000 Scientific Research Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... PHILADELPHIA (PRWEB) , ... July 24, 2017 , ... ... Health , two organizations that already work hand-in-hand on an Innovation Collaboration program, ... transform the access, quality, experience and cost of the care members and patients ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... (adipose) transfer systems announces the issuance of United States Patent Number 9,695,398 (the ... adipose filtration technology. The '398 and '324 patents cover methods and systems ...
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... July 24, 2017 , ... A ... focused on delivering end-to-end sleep health care at scale, indicates record-breaking adherence ... that adherence rates for positive airway pressure (PAP) therapy, the most widely utilized ...
(Date:7/24/2017)... Calif. (PRWEB) , ... July 24, 2017 , ... A ... from food addiction to sexual abuse, and how she has overcome them. “Forbidden Memories: ... instances in her life and how she has risen above. , In “Memories,” readers ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... York City-based market research firm Kalorama Information notes seven trends ... new products to new costs, to the threat of generic ... Potential Pipeline Disruptors . Among them are ... Age-Driven Growth - True Impact Moment Arriving   ... growing population and, to a more extreme extent, the aging ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
Breaking Medicine Technology: